Lv2
158 积分 2023-08-07 加入
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial
21分钟前
已完结
Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy
13小时前
已完结
Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution
20天前
已完结
Taming the inflamed heart
5个月前
已关闭
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
5个月前
已完结
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
5个月前
已完结
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
5个月前
已完结
The evolving landscape of obesity pharmacotherapy
5个月前
已完结
Tumors with microsatellite instability upregulate TREX1 to escape antitumor immunity
1年前
已完结